Cypress Wealth Services LLC Invests $381,000 in Astrazeneca Plc $AZN

Cypress Wealth Services LLC bought a new position in shares of Astrazeneca Plc (NYSE:AZN) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 4,146 shares of the company’s stock, valued at approximately $381,000.

A number of other large investors have also added to or reduced their stakes in the business. Braun Bostich & Associates Inc. acquired a new stake in shares of Astrazeneca during the 4th quarter worth about $201,000. USA Financial Formulas bought a new stake in shares of Astrazeneca during the 4th quarter worth about $925,000. Stillwater Capital Advisors LLC acquired a new position in Astrazeneca in the 4th quarter valued at about $225,000. Wealthcare Advisory Partners LLC raised its holdings in Astrazeneca by 1.8% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 23,544 shares of the company’s stock valued at $2,164,000 after acquiring an additional 418 shares during the period. Finally, Petros Family Wealth LLC bought a new position in Astrazeneca in the 4th quarter valued at about $236,000. Institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Morgan Stanley restated an “overweight” rating and set a $103.00 price objective on shares of Astrazeneca in a report on Wednesday, December 3rd. TD Cowen reiterated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, March 18th. Weiss Ratings assumed coverage on Astrazeneca in a report on Wednesday, March 11th. They set a “buy (b)” rating for the company. Guggenheim restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, December 3rd. Finally, Wall Street Zen raised Astrazeneca from a “hold” rating to a “buy” rating in a report on Friday, March 20th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $95.75.

Astrazeneca Stock Up 0.1%

Shares of AZN stock opened at $188.57 on Monday. Astrazeneca Plc has a fifty-two week low of $122.48 and a fifty-two week high of $212.71. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.72 and a current ratio of 0.94. The firm has a market capitalization of $292.45 billion, a price-to-earnings ratio of 32.48, a price-to-earnings-growth ratio of 1.42 and a beta of 0.32.

Astrazeneca Dividend Announcement

The firm also recently announced a dividend, which was paid on Monday, March 23rd. Shareholders of record on Friday, February 20th were given a $1.595 dividend. This represents a yield of 156.0%. The ex-dividend date was Friday, February 20th. Astrazeneca’s payout ratio is currently 66.26%.

Key Stories Impacting Astrazeneca

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Late‑stage trial win — Tozorakimab met primary goals in two pivotal trials, reducing chronic obstructive pulmonary disease flare‑ups versus placebo; the surprise positive readout is driving optimism about near‑term commercialization potential and pipeline momentum. AstraZeneca stock jumps 4% after surprise trial win for lung disease drug where rivals have failed
• Positive Sentiment: Regulatory and commercial implications — Reuters and other outlets highlight the meaningful reduction in flare‑ups and the significance of a successful phase III outcome for a disease area where competitors have struggled, which increases the drug’s value on AstraZeneca’s roadmap. AstraZeneca drug reduces COPD flare ups in late-stage trials
• Positive Sentiment: Clinical confirmation across endpoints — The Wall Street Journal and other reports emphasize that the trials hit their primary endpoints by lowering symptom worsening rates, reinforcing confidence in the data’s robustness and the potential for label and payer discussions. AstraZeneca Lung Disease Drug Candidate Hits Goals in Late-Stage Trials
• Neutral Sentiment: Stock movement vs. market — Coverage notes AZN advanced while broader markets were down, indicating the move is company‑specific (trial news/pipeline) rather than market driven. Astrazeneca (AZN) Advances While Market Declines: Some Information for Investors
• Neutral Sentiment: Analyst positioning — AstraZeneca has a consensus analyst rating of “Moderate Buy,” which supports the stock’s upside but does not by itself explain today’s move; analyst views may follow as investigators and investors digest full data and commercial assumptions. Astrazeneca Plc (NYSE:AZN) Receives Consensus Rating of “Moderate Buy” from Analysts

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.